Journal of Diabetes and Obesity
Herbal Anti-Hyperglycemic Compound Improves Glycemic Control and Insulin Sensitivity in Diabetic Rats
- 1Department of Biochemistry, University College of Medical Sciences (University of Delhi), Dilshad Garden, Delhi, India
- 2Department of Pathology, University College of Medical Sciences (University of Delhi), Dilshad Garden, Delhi, India
- 3Department of Biochemistry, All India institute of Medical Sciences, Ansari Nagar, New Delhi
Suman, B. Sharma, Department of Biochemistry, University College of Medical Sciences (University of Delhi), Dilshad Garden, Delhi- 110095, Tel: 91- 9818041119; E-mail: email@example.com
Sharma, S.B., et al. Herbal Anti-Hyperglycemic Compound Improves Glycemic Control and Insulin Sensitivity in Diabetic Rats. (2016) J Diabetes Obes 3(2): 1- 6.
© 2016 Sharma, S.B. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
KeywordsEugenia jambolana; FIIc; Diabetes; Tyrosine kinase; Dipeptidyl Peptidase 4; Pioglitazone; Wistar rats; HPLC
Objective: To study the effect of HPLC purified herbal anti-hyperglycemic active compound (FIIc) isolated from the fruit pulp of Eugenia jambolana in diabetic rats.
Methods: 24 male wistar rats were taken and diabetes was induced in group B, C and D rats (n = 6 each) by injecting Streptozotocin at a dose of 45 mg/kg of body weight 15 minutes after Nicotinamide at a dose 230 mg/kg body weight intraperitoneally after overnight fasting. Active compound (FIIc) was given to group C and Pioglitazone to group D at dose of 20 mg/kg of body weight orally for 4 weeks respectively. Glycemic and lipid profile, protein tyrosine kinase activity and serum DPP-4 levels were measured and compared between all the 4 study groups.
Results: Significant Improvement in body weight, glycemic profile, dyslipidemia and tyrosine kinase activity (4.90 ± 1.28 U/mg protein) were observed in FIIc treated rats at week 4 of the study compared to diabetic control rats. Serum DPP-4 levels (26.41 ± 0.43 pg/ml) were also found to be decreased in FIIc treated rats at week 4 of the study compared to diabetic control rats. This is possibly due to increased serum insulin levels and increased insulin sensitivity after treatment with active compound FIIc.
Conclusion: FIIc significantly reduced hyperglycemia and dyslipidemia by inhibiting DPP-4 levels and improves insulin sensitivity by increasing protein tyrosine kinase activity and serum insulin levels.